[{"id":"739a6ead-49a8-4524-b971-bdd0dec1f85b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05082025","created_at":"2021-10-18T12:53:16.001Z","updated_at":"2025-02-25T17:25:18.256Z","phase":"Phase 2","brief_title":"Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations","source_id_and_acronym":"NCT05082025","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PIK3CA • PGR • PTEN • PIK3R1 • PI3K","pipe":" | ","alterations":" ER positive • PIK3CA mutation • PTEN deletion","tags":["ER • PIK3CA • PGR • PTEN • PIK3R1 • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PIK3CA mutation • PTEN deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Aliqopa (copanlisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 09/27/2022","start_date":" 09/27/2022","primary_txt":" Primary completion: 10/29/2026","primary_completion_date":" 10/29/2026","study_txt":" Completion: 10/29/2026","study_completion_date":" 10/29/2026","last_update_posted":"2024-12-18"},{"id":"08e8d834-7d1c-43f8-b2b4-1023ee00f03e","acronym":"X31025","url":"https://clinicaltrials.gov/study/NCT03154294","created_at":"2025-09-13T10:56:31.458Z","updated_at":"2025-09-13T10:56:31.458Z","phase":"Phase 1","brief_title":"Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors","source_id_and_acronym":"NCT03154294 - X31025","lead_sponsor":"Avera McKennan Hospital \u0026 University Health Center","biomarkers":" PI3K","pipe":"","alterations":" ","tags":["PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • sapanisertib (CB-228) • serabelisib (MLN1117)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 07/06/2017","start_date":" 07/06/2017","primary_txt":" Primary completion: 11/20/2020","primary_completion_date":" 11/20/2020","study_txt":" Completion: 11/20/2022","study_completion_date":" 11/20/2022","last_update_posted":"2024-07-26"},{"id":"2638658d-5de1-4c1e-afa0-e9fef20584a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01327781","created_at":"2021-01-18T05:24:42.319Z","updated_at":"2024-07-02T16:35:17.724Z","phase":"Phase 1","brief_title":"Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer","source_id_and_acronym":"NCT01327781","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • HER-2 • ER • PGR • AKT1 • mTOR • IGF1R • NCOA3 • PI3K","pipe":" | ","alterations":" ER positive • HER-2 expression • EGFR expression","tags":["EGFR • HER-2 • ER • PGR • AKT1 • mTOR • IGF1R • NCOA3 • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 expression • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zonalta (Z-endoxifen hydrochloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 03/25/2011","start_date":" 03/25/2011","primary_txt":" Primary completion: 03/05/2017","primary_completion_date":" 03/05/2017","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2024-02-26"},{"id":"a01b13a9-a81d-4566-9d3e-266d627428f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02738866","created_at":"2021-01-18T13:24:51.951Z","updated_at":"2024-07-02T16:35:21.102Z","phase":"Phase 2","brief_title":"Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor","source_id_and_acronym":"NCT02738866","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" HER-2 • ER • PGR • PI3K","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + PGR positive • ESR1 mutation","tags":["HER-2 • ER • PGR • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + PGR positive • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/25/2016","start_date":" 10/25/2016","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-02"},{"id":"fae174c0-98ea-47ef-93cf-33fa869c7950","acronym":"","url":"https://clinicaltrials.gov/study/NCT05390710","created_at":"2022-05-25T12:57:02.573Z","updated_at":"2024-07-02T16:35:21.609Z","phase":"Phase 1","brief_title":"PhI to Solid Tumors and PhII to Locally Advanced or mTNBC","source_id_and_acronym":"NCT05390710","lead_sponsor":"Laekna Limited","biomarkers":" HER-2 • PD-L1 • ER • PGR • PTEN • BRCA • PI3K","pipe":" | ","alterations":" PD-L1 expression • PGR expression","tags":["HER-2 • PD-L1 • ER • PGR • PTEN • BRCA • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • afuresertib (LAE002) • LAE005"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 06/12/2021","start_date":" 06/12/2021","primary_txt":" Primary completion: 12/11/2023","primary_completion_date":" 12/11/2023","study_txt":" Completion: 12/11/2023","study_completion_date":" 12/11/2023","last_update_posted":"2024-01-31"},{"id":"ff5bc58c-ee75-4fcb-9b27-1953531ffbb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05383482","created_at":"2022-05-20T18:58:22.901Z","updated_at":"2024-07-02T16:35:39.188Z","phase":"Phase 1/2","brief_title":"Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1","source_id_and_acronym":"NCT05383482","lead_sponsor":"Laekna Limited","biomarkers":" HER-2 • KRAS • ALK • PTEN • PI3K","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • KRAS wild-type • RAS wild-type • ALK negative","tags":["HER-2 • KRAS • ALK • PTEN • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • KRAS wild-type • RAS wild-type • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Tyvyt (sintilimab) • albumin-bound paclitaxel • afuresertib (LAE002)"],"overall_status":"Recruiting","enrollment":" Enrollment 167","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-08-23"},{"id":"6eb97f2c-ec9d-435c-8cbb-be3b4fce8c70","acronym":"","url":"https://clinicaltrials.gov/study/NCT03284502","created_at":"2021-01-18T16:13:34.748Z","updated_at":"2024-07-02T16:35:41.554Z","phase":"Phase 1","brief_title":"HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT03284502","lead_sponsor":"Hanmi Pharmaceutical Company Limited","biomarkers":" KRAS • BRAF • NRAS • PI3K","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • KRAS G13D • RAS mutation • BRAF fusion • KRAS G13 • NRAS G13","tags":["KRAS • BRAF • NRAS • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • KRAS G13D • RAS mutation • BRAF fusion • KRAS G13 • NRAS G13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Cotellic (cobimetinib) • belvarafenib (RG6185)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 148","initiation":"Initiation: 05/22/2017","start_date":" 05/22/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-08-01"},{"id":"abe9b208-e2d6-42d9-bba9-5f4961eb8fa8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01700582","created_at":"2021-01-18T07:23:34.397Z","updated_at":"2024-07-02T16:35:42.321Z","phase":"","brief_title":"French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings","source_id_and_acronym":"NCT01700582","lead_sponsor":"Intergroupe Francophone de Cancerologie Thoracique","biomarkers":" HER-2 • KRAS • BRAF • ALK • EML4 • RAS • PI3K","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • HER-2 mutation • RAS mutation • ALK translocation","tags":["HER-2 • KRAS • BRAF • ALK • EML4 • RAS • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • HER-2 mutation • RAS mutation • ALK translocation"],"overall_status":"Completed","enrollment":" Enrollment 17664","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 04/01/2013","study_completion_date":" 04/01/2013","last_update_posted":"2023-07-21"},{"id":"a0b2e315-c24b-40d2-841a-430e9d381808","acronym":"BEAUTY","url":"https://clinicaltrials.gov/study/NCT02022202","created_at":"2021-01-18T09:15:13.266Z","updated_at":"2024-07-02T16:35:58.080Z","phase":"","brief_title":"Breast Cancer Genome Guided Therapy Study (BEAUTY)","source_id_and_acronym":"NCT02022202 - BEAUTY","lead_sponsor":"Mayo Clinic","biomarkers":" EGFR • HER-2 • KRAS • BRAF • PTEN • PI3K","pipe":" | ","alterations":" HER-2 positive • KRAS mutation • EGFR mutation • BRAF mutation • HER-2 amplification • HER-2 negative • PTEN mutation • KIT mutation • EGFR mutation + PTEN mutation","tags":["EGFR • HER-2 • KRAS • BRAF • PTEN • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • KRAS mutation • EGFR mutation • BRAF mutation • HER-2 amplification • HER-2 negative • PTEN mutation • KIT mutation • EGFR mutation + PTEN mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 05/01/2014","primary_completion_date":" 05/01/2014","study_txt":" Completion: 12/14/2032","study_completion_date":" 12/14/2032","last_update_posted":"2023-01-06"},{"id":"bb882abd-a09d-45b4-b16d-33846bd77bd9","acronym":"PIKNIC","url":"https://clinicaltrials.gov/study/NCT02506556","created_at":"2021-03-02T12:19:35.132Z","updated_at":"2025-02-25T15:42:30.490Z","phase":"Phase 2","brief_title":"Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer","source_id_and_acronym":"NCT02506556 - PIKNIC","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" EGFR • HER-2 • KRAS • ER • ALK • PIK3CA • PGR • NRAS • PTEN • HRAS • AKT1 • PIK3R1 • INPP4B • PI3K • PIK3R3","pipe":" | ","alterations":" KRAS mutation • ER positive • EGFR mutation • HER-2 negative • PIK3CA mutation • EGFR amplification • ALK mutation","tags":["EGFR • HER-2 • KRAS • ER • ALK • PIK3CA • PGR • NRAS • PTEN • HRAS • AKT1 • PIK3R1 • INPP4B • PI3K • PIK3R3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ER positive • EGFR mutation • HER-2 negative • PIK3CA mutation • EGFR amplification • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 09/07/2015","start_date":" 09/07/2015","primary_txt":" Primary completion: 10/26/2021","primary_completion_date":" 10/26/2021","study_txt":" Completion: 10/26/2021","study_completion_date":" 10/26/2021","last_update_posted":"2022-08-16"},{"id":"160de920-0123-4feb-9f61-df7a1bc389da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03765333","created_at":"2021-01-18T18:37:59.192Z","updated_at":"2024-07-02T16:36:06.197Z","phase":"","brief_title":"GETNE Registration of Thyroid Cancer","source_id_and_acronym":"NCT03765333","lead_sponsor":"Grupo Espanol de Tumores Neuroendocrinos","biomarkers":" BRAF • TP53 • RET • PTEN • RAS • PAX8 • PI3K","pipe":" | ","alterations":" TP53 mutation • BRAF mutation • PTEN mutation • RAS mutation • RET mutation","tags":["BRAF • TP53 • RET • PTEN • RAS • PAX8 • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRAF mutation • PTEN mutation • RAS mutation • RET mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/28/2019","start_date":" 05/28/2019","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-08-03"},{"id":"098c35a0-2efb-4198-9e37-d404a306dc5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03563651","created_at":"2021-01-18T17:32:18.199Z","updated_at":"2024-07-02T16:36:20.545Z","phase":"","brief_title":"Collection of Blood, Urine, and Stool to Monitor MetastaticColorectal Cancers","source_id_and_acronym":"NCT03563651","lead_sponsor":"University of Southern California","biomarkers":" KRAS • BRAF • PI3K","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • KRAS wild-type • RAS wild-type","tags":["KRAS • BRAF • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • KRAS wild-type • RAS wild-type"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 02/06/2014","start_date":" 02/06/2014","primary_txt":" Primary completion: 05/28/2020","primary_completion_date":" 05/28/2020","study_txt":" Completion: 05/28/2020","study_completion_date":" 05/28/2020","last_update_posted":"2021-11-18"},{"id":"a041e75d-dea4-42aa-90f8-c25cae180d4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05054166","created_at":"2021-09-23T17:52:59.544Z","updated_at":"2024-07-02T16:36:24.082Z","phase":"","brief_title":"Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study","source_id_and_acronym":"NCT05054166","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" HER-2 • mTOR • PI3K","pipe":" | ","alterations":" HER-2 negative • MTOR mutation","tags":["HER-2 • mTOR • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 05/01/2021","start_date":" 05/01/2021","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/30/2021","study_completion_date":" 08/30/2021","last_update_posted":"2021-09-23"},{"id":"e1eb53c8-559c-4659-bbff-a5b5bcd0ecee","acronym":"Neo ALTTO","url":"https://clinicaltrials.gov/study/NCT00553358","created_at":"2021-01-17T17:13:14.615Z","updated_at":"2024-07-02T16:36:24.205Z","phase":"Phase 3","brief_title":"Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study","source_id_and_acronym":"NCT00553358 - Neo ALTTO","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • PIK3CA • PTEN • PI3K","pipe":" | ","alterations":" HR positive • HER-2 amplification • HER-2 expression • PTEN expression","tags":["HER-2 • PIK3CA • PTEN • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 amplification • HER-2 expression • PTEN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 455","initiation":"Initiation: 01/05/2008","start_date":" 01/05/2008","primary_txt":" Primary completion: 05/27/2010","primary_completion_date":" 05/27/2010","study_txt":" Completion: 12/23/2019","study_completion_date":" 12/23/2019","last_update_posted":"2021-09-21"},{"id":"3d16db99-72b0-437e-b12d-7a8d794c3273","acronym":"","url":"https://clinicaltrials.gov/study/NCT01310231","created_at":"2021-07-10T10:52:43.989Z","updated_at":"2024-07-02T16:36:31.953Z","phase":"Phase 2","brief_title":"A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer","source_id_and_acronym":"NCT01310231","lead_sponsor":"Ozmosis Research Inc.","biomarkers":" STK11 • PI3K","pipe":"","alterations":" ","tags":["STK11 • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • metformin"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 08/22/2011","start_date":" 08/22/2011","primary_txt":" Primary completion: 07/14/2016","primary_completion_date":" 07/14/2016","study_txt":" Completion: 03/26/2018","study_completion_date":" 03/26/2018","last_update_posted":"2021-04-14"},{"id":"c6482f62-b29d-422c-ac88-2950e4e5187d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00827359","created_at":"2021-01-18T03:08:51.503Z","updated_at":"2025-02-25T15:49:51.116Z","phase":"Phase 2","brief_title":"Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT00827359","lead_sponsor":"Beth Israel Deaconess Medical Center","biomarkers":" mTOR • PI3K","pipe":" | ","alterations":" MTOR mutation","tags":["mTOR • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2009","start_date":" 03/01/2009","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2021-02-24"},{"id":"c1924624-7573-4ba0-bec2-9619777dfc8f","acronym":"BELLE-2","url":"https://clinicaltrials.gov/study/NCT01610284","created_at":"2021-01-18T06:53:40.260Z","updated_at":"2024-07-02T16:36:41.686Z","phase":"Phase 3","brief_title":"Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor","source_id_and_acronym":"NCT01610284 - BELLE-2","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • PI3K","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 1147","initiation":"Initiation: 08/07/2012","start_date":" 08/07/2012","primary_txt":" Primary completion: 04/29/2015","primary_completion_date":" 04/29/2015","study_txt":" Completion: 04/19/2019","study_completion_date":" 04/19/2019","last_update_posted":"2020-08-25"},{"id":"73552f87-164d-42a3-b749-7eef35e0b7c2","acronym":"ASPIK French","url":"https://clinicaltrials.gov/study/NCT02945033","created_at":"2022-01-05T22:01:00.037Z","updated_at":"2024-07-02T16:36:54.260Z","phase":"Phase 3","brief_title":"Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk","source_id_and_acronym":"NCT02945033 - ASPIK French","lead_sponsor":"University Hospital, Rouen","biomarkers":" PI3K","pipe":"","alterations":" ","tags":["PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 264","initiation":"Initiation: 07/12/2018","start_date":" 07/12/2018","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2019-10-24"},{"id":"9b65967e-5e2b-41f4-9a9f-64c8bccabb30","acronym":"VISNU-1","url":"https://clinicaltrials.gov/study/NCT01640405","created_at":"2021-01-18T07:03:25.809Z","updated_at":"2024-07-02T16:37:00.641Z","phase":"Phase 3","brief_title":"Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells","source_id_and_acronym":"NCT01640405 - VISNU-1","lead_sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","biomarkers":" BRAF • RAS • PI3K","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • RAS • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 350","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2019-04-11"},{"id":"5027d33d-b47d-406f-9cd4-b025a7662116","acronym":"","url":"https://clinicaltrials.gov/study/NCT00885755","created_at":"2021-01-18T03:23:20.549Z","updated_at":"2024-07-02T16:37:12.696Z","phase":"Phase 2","brief_title":"A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT00885755","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • MET • PTEN • PI3K","pipe":" | ","alterations":" HER-2 positive • EGFR positive","tags":["HER-2 • MET • PTEN • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 08/13/2009","start_date":" 08/13/2009","primary_txt":" Primary completion: 02/18/2013","primary_completion_date":" 02/18/2013","study_txt":" Completion: 02/18/2013","study_completion_date":" 02/18/2013","last_update_posted":"2018-03-29"},{"id":"1cee3f20-0b6e-4714-89f5-55b8c7e1487f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03273595","created_at":"2021-01-18T16:10:05.742Z","updated_at":"2024-07-02T16:37:18.153Z","phase":"Phase 2","brief_title":"Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer","source_id_and_acronym":"NCT03273595","lead_sponsor":"Xijing Hospital","biomarkers":" HER-2 • PTEN • PI3K","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2 • PTEN • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • lapatinib • cyclophosphamide • epirubicin"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2017-09-06"},{"id":"c5ea7c38-7155-40d3-89c0-c0b9a663628f","acronym":"BELLE-4","url":"https://clinicaltrials.gov/study/NCT01572727","created_at":"2021-01-18T06:40:31.165Z","updated_at":"2024-07-02T16:37:24.573Z","phase":"Phase 2/3","brief_title":"A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation","source_id_and_acronym":"NCT01572727 - BELLE-4","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • PI3K","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 416","initiation":"Initiation: 08/01/2012","start_date":" 08/01/2012","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 06/01/2015","study_completion_date":" 06/01/2015","last_update_posted":"2017-03-09"}]